Streetbeat News

Products Services

ELAN

Elanco Animal Health has announced the completion of major technical sections for Zenrelia, with FDA final approval expected in late Q3 2024. Additionally, the final FDA approval for Credelio Quattro is now anticipated in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 10:31 am

BB

LYV

UNH

BlackBerry Limited (NYSE:BB) shares are trading higher in the premarket session after reporting first-quarter revenues of $144 million, beating estimates. The company's Cybersecurity segment exceeded guidance, and its IoT segment achieved 18% year-over-year revenue growth. The company also reported a smaller-than-expected loss and maintained its full-year forecast.

Portfolio Pulse from Nabaparna Bhattacharya

June 27, 2024 | 10:25 am

AMZN

Amazon has invested $72 million into its Indian payments business to compete with Google Pay and Walmart-backed PhonePe. This brings Amazon's total investment in the platform to $113.8 million this year. The move aims to strengthen Amazon's position in India's rapidly growing digital payments market.

Portfolio Pulse from Benzinga Neuro

June 27, 2024 | 10:19 am

AMZN

PDD

VCR

XLY

Amazon is preparing to launch a new bargain section on its site, targeting overseas consumers with affordable items shipped from China. This move aims to compete with Shein and Temu. The new marketplace will feature unbranded fashion, home goods, and daily necessities with delivery times of 9 to 11 days. Amazon will start signing up Chinese sellers this summer and begin accepting inventory in the fall.

Portfolio Pulse from Shivani Kumaresan

June 27, 2024 | 10:13 am

LNZA

LanzaTech Global, Inc. (NASDAQ:LNZA) and LanzaJet, Inc. have launched CirculAir™, a new technology to convert waste and renewable power into sustainable aviation fuel (SAF). This innovation aims to significantly reduce aviation emissions and overcome historical barriers to SAF adoption.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 10:07 am

NKTX

Nkarta has started the Ntrust-1 clinical trial for NKX019 in lupus nephritis and received FDA clearance for a second IND application for NKX019 in autoimmune diseases. The Ntrust-2 trial will target systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. Clinical data from both trials are expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 10:04 am

ENTO

Entero Therapeutics (NASDAQ:ENTO) has published a new research paper in Clinical Gastroenterology and Hepatology, introducing a composite morphometric duodenal biopsy mucosal scale for celiac disease. This new scale, VCIEL, combines architectural changes and inflammation measures to improve the accuracy of histological evaluations.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 10:04 am

NKTX

Nkarta has initiated the Ntrust-1 study of NKX019 in lupus nephritis, with the first patient in screening. Additionally, the FDA has cleared a second investigational new drug application for NKX019 in autoimmune disease.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 10:04 am

MS

Morgan Stanley (NYSE:MS) is launching an AI-powered assistant named Debrief to enhance the workflow of its financial advisors. Built using OpenAI's GPT-4, Debrief will automate note-taking during client meetings, potentially increasing client engagement and business growth. This move aligns with the growing adoption of AI in the financial sector.

Portfolio Pulse from Benzinga Neuro

June 27, 2024 | 9:58 am

BP

EIPX

HJEN

BP p.l.c. (NYSE:BP) is reportedly shifting its focus from renewable energy projects to oil and gas, implementing a hiring freeze and halting new offshore wind projects. This strategic shift, led by CEO Murray Auchincloss, aims to prioritize investments in oil and gas assets, particularly in the Gulf of Mexico and U.S. onshore shale basins. The move has affected BP's stock performance, with renewable energy returns declining and oil and gas profits soaring.

Portfolio Pulse from Lekha Gupta

June 27, 2024 | 9:52 am